The DOI matches its Crossref record.
Combination Therapy with Lopinavir/Ritonavir, Ribavirin and Interferon-α for Middle East Respiratory Syndrome
Open accessAbstract
Since the first report of Middle East respiratory syndrome (MERS) in 2012 in Saudi Arabia, no standard treatment guideline has been set despite the virulence of MERS-coronavirus (CoV) and the high case-fatality rate. The outbreak in South Korea in 2015 demonstrates that MERS outbreaks can occur outside of the Middle East. The combination of ribavirin and interferon-α has been the most widely used therapy for this infection. However, due to the varying results of treatment with these drugs, a new antiviral combination regimen is urgently needed. This is a case report of use of lopinavir/ritonavir-based combination antiviral therapy for a patient with MERS-CoV infection.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19
Cao, B., Wang, Y., Wen, D., Liu, W., Wang, J., Fan, G., Ruan, L., Song, B., Cai, Y., Wei, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001282 · Cited by 5,187
SARS and MERS: recent insights into emerging coronaviruses
de Wit, E., van Doremalen, N., Falzarano, D., & Munster, V. J. (2016) · Nature Reviews Microbiology · doi:10.1038/nrmicro.2016.81 · Cited by 3,510
Sheahan, T. P., Sims, A. C., Leist, S. R., Schäfer, A., Won, J., Brown, A. J., Montgomery, S. A., Hogg, A., Babusis, D., Clarke, M. O., et al. (2020) · Nature Communications · doi:10.1038/s41467-019-13940-6 · Cited by 1,738
Virology, Epidemiology, Pathogenesis, and Control of COVID-19
Jin, Y., Yang, H., Ji, W., Wu, W., Chen, S., Zhang, W., & Duan, G. (2020) · Viruses · doi:10.3390/v12040372 · Cited by 1,603
Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations
Phua, J., Weng, L., Ling, L., Egi, M., Lim, C.-M., Divatia, J. V., Shrestha, B. R., Arabi, Y. M., Ng, J., Gomersall, C. D., et al. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30161-2 · Cited by 1,509
Potential interventions for novel coronavirus in China: A systematic review
Zhang, L., & Liu, Y. (2020) · Journal of Medical Virology · doi:10.1002/jmv.25707 · Cited by 1,348
IFN-I response timing relative to virus replication determines MERS coronavirus infection outcomes
Channappanavar, R., Fehr, A. R., Zheng, J., Wohlford-Lenane, C., Abrahante, J. E., Mack, M., Sompallae, R., McCray, P. B., Meyerholz, D. K., & Perlman, S. (2019) · Journal of Clinical Investigation · doi:10.1172/jci126363 · Cited by 556
Yao, T., Qian, J., Zhu, W., Wang, Y., & Wang, G. (2020) · Journal of Medical Virology · doi:10.1002/jmv.25729 · Cited by 469
COVID-19 and kidney transplantation: Results from the TANGO International Transplant Consortium
Cravedi, P., Mothi, S. S., Azzi, Y., Haverly, M., Farouk, S. S., Pérez-Sáez, M. J., Redondo-Pachón, M. D., Murphy, B., Florman, S., Cyrino, L. G., et al. (2020) · American Journal of Transplantation · doi:10.1111/ajt.16185 · Cited by 390
Nanotechnology for COVID-19: Therapeutics and Vaccine Research
Chauhan, G., Madou, M. J., Kalra, S., Chopra, V., Ghosh, D., & Martinez-Chapa, S. O. (2020) · ACS Nano · doi:10.1021/acsnano.0c04006 · Cited by 385
Novel coronavirus treatment with ribavirin: Groundwork for an evaluation concerning COVID‐19
Khalili, J. S., Zhu, H., Mak, N. S. A., Yan, Y., & Zhu, Y. (2020) · Journal of Medical Virology · doi:10.1002/jmv.25798 · Cited by 359
Individual risk management strategy and potential therapeutic options for the COVID-19 pandemic
Gasmi, A., Noor, S., Tippairote, T., Dadar, M., Menzel, A., & Bjørklund, G. (2020) · Clinical Immunology · doi:10.1016/j.clim.2020.108409 · Cited by 305
COVID-19 and Cancer: a Comprehensive Review
Gosain, R., Abdou, Y., Singh, A., Rana, N., Puzanov, I., & Ernstoff, M. S. (2020) · Current Oncology Reports · doi:10.1007/s11912-020-00934-7 · Cited by 285
Current status of potential therapeutic candidates for the COVID-19 crisis
Zhang, J., Xie, B., & Hashimoto, K. (2020) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2020.04.046 · Cited by 283
Trends and strategies to combat viral infections: A review on FDA approved antiviral drugs
Tompa, D. R., Immanuel, A., Srikanth, S., & Kadhirvel, S. (2021) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2021.01.076 · Cited by 257
And the MIRACLE trial group, Arabi, Y. M., Alothman, A., Balkhy, H. H., Al-Dawood, A., AlJohani, S., Al Harbi, S., Kojan, S., Al Jeraisy, M., Deeb, A. M., et al. (2018) · Trials · doi:10.1186/s13063-017-2427-0 · Cited by 253
Molecular mechanisms and epidemiology of COVID-19 from an allergist’s perspective
Hosoki, K., Chakraborty, A., & Sur, S. (2020) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2020.05.033 · Cited by 63
Treatments Administered to the First 9152 Reported Cases of COVID-19: A Systematic Review
Fajgenbaum, D. C., Khor, J. S., Gorzewski, A., Tamakloe, M.-A., Powers, V., Kakkis, J. J., Repasky, M., Taylor, A., Beschloss, A., Hernandez-Miyares, L., et al. (2020) · Infectious Diseases and Therapy · doi:10.1007/s40121-020-00303-8 · Cited by 52
Metadata
- Authors
- Kim, U. J., Won, E.-J., Kee, S.-J., Jung, S.-I., & Jang, H.-C.
- Venue
- Antiviral Therapy
- Publisher
- SAGE Publications
- Published
- 2015-07-01
- Volume
- 21
- Issue
- 5
- Pages
- 455-459
- ISSN
- 1359-6535 (ISSN-L)
- 2040-2058
- OpenAlex
- W2403765756
- Cited by
- 192
- References
- 0
- FWCI
- 3.37
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.